Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 952-960

  Yamai, Hiromichi ^a   Sawada, Naruhiko ^a   Yoshida, Takahiro ^a   Seike, Jyunichi ^a   Takizawa, Hiromitsu ^a   Kenzaki, Koichiro ^a   Miyoshi, Takanori ^a   Kondo, Kazuya ^a   Bando, Yoshimi ^a   Ohnishi, Yoshinari ^b   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Combinational therapy; Esophageal cancer; Japanese apricot extract; Peritoneal metastasis; Triterpene

Indexed keywords

BETULIC ACID; CISPLATIN; FLUOROURACIL; IRINOTECAN; OLEANOLIC ACID; PLANT EXTRACT; PRUNUS ARMENIACA EXTRACT; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; URSOLIC ACID;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APRICOT; ARTICLE; ASCITES; CANCER INHIBITION; CANCER SIZE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM METASTASIS; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG INTERACTIONS; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; PERITONEAL NEOPLASMS; PLANT PREPARATIONS; PRUNUS; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650097012     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24433     Document Type: Article

References (48)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220:364-72.
4. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232: 225-32.
5. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003;21: 4592-6.
6. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697-702.
7. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003;97:1616-23.
8. Wilson M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, Cohn HE, Rosato FE, Sr, Berger AC. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Sur Res 2008;146:11-15.
9. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004;198:205-11.
10. Kidokoro T, Watanabe Y, Yagasaki K. Studies on esophageal carcinoma cases died within three months after surgical treatment in JAPAN. Jpn J Gastroenterol Surg 1998;21:1003-14.
11. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
12. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-5.
13. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006;66:3347-50.
14. Sawada N, Kataoka K, Kondo K, Arimochi H, Fujino H, Takahashi Y, Miyoshi T, Kuwahara T, Monden Y, Ohnishi Y. Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer 2004;90:1672-8.
15. Bunpo P, Kataoka K, Arimochi H, Nakayama H, Kuwahara T, Vinitketkumnuen U, Ohnishi Y. Inhibitory effects of asiatic acid and CPT-11 on growth of HT-29 cells. J Med Invest 2005;52:65-73.
16. Saimaru H, Orihara Y, Tansakul P, Kang YH, Shibuya M, Ebizuka Y. Production of triterpene acids by cell suspension cultures of Olea europaea. Chem Pharm Bull 2007;55:784-8.
17. Adachi M, Suzuki Y, Mizuta T, Osawa T, Adachi T, Osaka K, Suzuki K, Shiojima K, Arai Y, Masuda K, Uchiyama M, Oyamada T, et al. The "Prunus mume Sieb. et Zucc" (Ume) is a rich natural source of novel anti-cancer substance. Int J Food Prop 2007;10:375-84.
18. Okada T, Sawada T, Osawa T, Adachi M, Kubota K. A novel anticancer substance. MK615, from ume, a variety of. Japanese apricot, inhibits growth of hepatocellular carcinoma cells by suppressing. Aurora. A kinase activity. Hepatogastroenterology 2007;54:1770-4.
19. Okada T, Sawada T, Osawa T, Adachi M, Kubota K. MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases. World J Gastroenterol 2008;14:1378-82.
20. Iizuka N, Hirose K, Noma T, Hazama S, Tangoku A, Hayashi H, Abe T, Yamamoto K, Oka M. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer 1999;81:469-75.
21. Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T, Suzuki T. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996;16:1001-6.
22. Murakami T, Nakamura M, Kusanagi H, Suzuki T. Establishment and characterization of human esophageal carcinoma cell lines-especially the role of the serum-free culture. Nippon Geka Gakkai Zasshi 1991;92:1563-70.
23. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
24. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-335.
25. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
26. Machida S, Saga Y, Takei Y, Mizuno I, Takayama T, Kohno T, Konno R, Ohwada M, Suzuki M. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer 2005;114:224-9.
27. Wyllie A. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
28. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6.
29. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007;25:3210-16.
30. Yu D, Morris-Natschke SL, Lee KH. New developments in natural products-based anti-AIDS research. Med Res Rev 2007;27:108-32.
31. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69.
32. Sakurawi K, Yasuda F, Tozyo T, Nakamura M, Sato T, Kikuchi J, Terui Y, Ikenishi Y, Iwata T, Takahashi K, Konoike T, Mihara S, et al. Endothelin receptor antagonist triterpenoid, myriceric acid A, isolated from Myrica cerifera, and structure activity relationships of its derivatives. Chem Pharm Bull 1996;44:343-51.
33. Nakagawa A, Sawada T, Okada T, Ohsawa T, Adachi M, Kubota K. New antineoplastic agent. MK615, from. UME (a variety of) Japanese apricot inhibits growth of breast cancer cells in vitro. Breast J 2007;13:44-9.
34. Kondo K, Yamasaki S, Sugie T, Teratani N, Kan T, Imamura M, Shimada Y. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer 2006;118:230-42.
35. Akutsu Y, Matsubara H, Urashima T, Komatsu A, Sakata H, Nishimori T, Yoneyama Y, Hoshino I, Murakami K, Usui A, Kano M, Ochiai T. Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice. Int J Oncol 2007;31:509-15.
36. Eder-Czembirek C, Czembirek C, Erovic BM, Selzer E, Turhani D, Vormittag L, Thurnher D. Combination of betulinic acid with cisplatin-different cytotoxic effects in two head and neck cancer cell lines. Oncol Rep 2005;14:667-71.
37. Hsu YL, Kuo PL, Lin CC. Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci 2004;75:2303-16.
38. Hernández-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Bañón-Rodríguez I, Esteller M, Moreno-Bueno G, Palacios J. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 2006;119:1164-75.
39. Zalatnai A. Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors. In Vivo 2005;19:85-91.
40. Gajate C, Barasoain I, Andreu JM, Mollinedo F. Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2′,3′,4′-trimethoxyphenyl)-2,4, 6-cycloheptatrien-1 -one: protection by Bcl-2 and Bcl-X(L) and cell cycle arrest. Cancer Res 2000;60:2651-9.
41. Kim JH, Ju EM, Lee DK, Hwang HJ. Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells. Anticancer Res 2002;22:1855-9.
42. Giammarioli AM, Maselli A, Casagrande A, Gambardella L, Gallina A, Spada M, Giovannetti A, Proietti E, Malorni W, Pierdominici M. Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res 2008;68:5291-300.
43. Rzeski W, Stepulak A, Szymański M, Sifringer M, Kaczor J, Wejksza K, Zdzisińska B, Kandefer-Szerszeń M. Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol 2006;374:11-20.
44. Duval RE, Harmand PO, Jayat-Vignoles C, Cook-Moreau J, Pinon A, Delage C, Simon A. Differential involvement of mitochondria during ursolic acid-induced apoptotic process in HaCaT and M4Beu cells. Oncol Rep 2008;19:145-9.
45. Kim DK, Baek JH, Kang CM, Yoo MA, Sung JW, Chung HY, Kim ND, Choi YH, Lee SH, Kim KW. Apoptotic activity of ursolic acid may correlate with the inhibition of initiation of DNA replication. Int J Cancer 2000;87:629-36.
46. Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005;96:323-32.
47. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 2006;12:1828-38.
48. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007;67:2816-23.